Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy

References

• SieperJRudwaleitMKhanMABraunJConcepts and epidemiology of spondyloarthritisBest Pract Res Clin Rheumatol200620340141716777573
   PubMed Web of Science ®Google Scholar
• SykesMPDollHSenguptaRGaffneyKDelay to diagnosis in axial spondyloarthritis: are we improving in the UK?Rheumatology (Oxford)201554122283228426283680
   PubMed Web of Science ®Google Scholar
• FeldtkellerEKhanMAvan der HeijdeDvan der LindenSBraunJAge at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitisRheumatol Int2003232616612634937
   PubMed Web of Science ®Google Scholar
• van der LindenSValkenburgHACatsAEvaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteriaArthritis Rheum19842743613686231933
   PubMed Web of Science ®Google Scholar
• BaraliakosXBraunJNon-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?RMD Open20151Suppl 1e00005326557375
   PubMedGoogle Scholar
• KiltzUBaraliakosXKarakostasPThe degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort studyAnn Rheum Dis20127171207121122523430
   PubMed Web of Science ®Google Scholar
• RudwaleitMvan der HeijdeDLandeweRThe development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selectionAnn Rheum Dis200968677778319297344
   PubMed Web of Science ®Google Scholar
• DeodharAMittalMReillyPAnkylosing spondylitis diagnosis in US patients with back pain: identifying providers involved and factors associated with rheumatology referral delayClin Rheumatol20163571769177626987341
   PubMed Web of Science ®Google Scholar
• SalvadoriniGBandinelliFDelle SedieAAnkylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decadesClin Exp Rheumatol201230456156522510360
   PubMed Web of Science ®Google Scholar
• PoddubnyyDRudwaleitMHaibelHRates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritisAnn Rheum Dis20117081369137421622969
   PubMed Web of Science ®Google Scholar
• Sampaio-BarrosPDBertoloMBKraemerMHMarques-NetoJFSamaraAMUndifferentiated spondyloarthropathies: a 2-year followup studyClin Rheumatol200120320120611434474
   PubMed Web of Science ®Google Scholar
• Ortega CastroRFont UgaldePCastro VillegasMCDifferent clinical expression of patients with ankylosing spondylitis according to gender in relation to time since onset of disease. Data from REG-ISPONSERReumatol Clin201394221225 Spanish [with English abstract]23474378
   PubMedGoogle Scholar
• TournadreAPereiraBLhosteADifferences between women and men with recent-onset axial spondyloarthritis: results from a prospective multicenter French cohortArthritis Care Res (Hoboken)20136591482148923463610
   PubMed Web of Science ®Google Scholar
• WallisDInmanRDRecognition of preclinical and early disease in axial spondyloarthritisRheum Dis Clin North Am201440468569725437285
   PubMed Web of Science ®Google Scholar
• DeodharAReveilleJDvan den BoschFThe concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis International Society in response to the US Food and Drug Administration’s comments and concernsArthritis Rheumatol201466102649265625154344
   PubMed Web of Science ®Google Scholar
• RumyantsevaDGDubininaTVDeminaABAnkylosing spondylitis and non-radiographic axial spondyloarthritis: two stages of disease?Ter Arkh20178953337 Russian [with English abstract]
   Web of Science ®Google Scholar
• de WinterJJvan MensLJvan der HeijdeDLandeweRBaetenDLPrevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysisArthritis Res Ther20161819627586785
   PubMed Web of Science ®Google Scholar
• WallmanJKKapetanovicMCPeterssonIFGeborekPKristensenLEComparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients—baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practiceArthritis Res Ther20151737826703005
   PubMed Web of Science ®Google Scholar
• SongIHWeissAHermannKGSimilar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trialAnn Rheum Dis201372682382523172749
   PubMed Web of Science ®Google Scholar
• SongIHHermannKGHaibelHConsistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trialJ Rheumatol201441102034204025028375
   PubMed Web of Science ®Google Scholar
• RudwaleitMClaudepierrePWordsworthPEffectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitisJ Rheumatol200936480180819273449
   PubMed Web of Science ®Google Scholar
• RudwaleitMSchwarzloseSHilgertESListingJBraunJSieperJMRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitisAnn Rheum Dis20086791276128118006539
   PubMed Web of Science ®Google Scholar
• RudwaleitMListingJBrandtJBraunJSieperJPrediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitisAnn Rheum Dis200463666567015037444
   PubMed Web of Science ®Google Scholar
• Acosta-FelquerMLRosaJSorianoERAn evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapyOpen Access Rheumatol20168374427843368
   PubMedGoogle Scholar
• GoelNStephensSCertolizumab pegolMAbs20102213714720190560
   PubMed Web of Science ®Google Scholar
• NesbittAFossatiGBerginMMechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agentsInflamm Bowel Dis200713111323133217636564
   PubMed Web of Science ®Google Scholar
• van der HeijdeDDougadosMLandeweRSustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpARheumatology (Oxford)20175691498150928498975
   PubMed Web of Science ®Google Scholar
• LandewéRBraunJDeodharAEfficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 studyAnn Rheum Dis2014731394724013647
   PubMed Web of Science ®Google Scholar
• BraunJBaraliakosXHermannKGEffect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritisRMD Open201731e00043028848654
   PubMed Web of Science ®Google Scholar
• SieperJKivitzAvan TubergenAImpact of certolizumab pegol on patient-reported outcomes in patients with axial spondyloarthritisArthritis Care Res (Hoboken)201567101475148025832312
   PubMed Web of Science ®Google Scholar
• SieperJKivitzAvan TubergenALong-term maintenance of improvements in patient-reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis: 96-week results of the RAPID-axSpA StudyValue Health2014177A385A386
   Web of Science ®Google Scholar
• SieperJLandeweRRudwaleitMEffect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trialArthritis Rheumatol201567366867725470228
   PubMed Web of Science ®Google Scholar
• MaksymowychWPInmanRDSalonenDSpondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitisArthritis Rheum200553570370916208659
   PubMed Web of Science ®Google Scholar
• LukasCBraunJvan der HeijdeDScoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experimentJ Rheumatol200734486287017407241
   PubMed Web of Science ®Google Scholar
• SeprianoARegelAvan der HeijdeDEfficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritisRMD Open201731e00039628176964
   PubMed Web of Science ®Google Scholar
• DougadosMvan der HeijdeDSieperJSymptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trialArthritis Rheumatol20146682091210224891317
   PubMed Web of Science ®Google Scholar
• SieperJvan der HeijdeDDougadosMEfficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)Ann Rheum Dis201372681582222772328
   PubMed Web of Science ®Google Scholar
• SieperJvan der HeijdeDDougadosMA randomized, double-blind, placebo-controlled, sixteen-week study of subcutaneous golimumab in patients with active nonradiographic axial spondyloarthritisArthritis Rheumatol201567102702271226139307
   PubMed Web of Science ®Google Scholar
• KamedaHNishidaKNannkiTWatanabeAOshimaYMomoharaSSafety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis: interim analysis of post-marketing surveillanceNihon Rinsho Meneki Gakkai Kaishi2017403196205 Japanese [with English abstract]28747607
   PubMedGoogle Scholar
• ZhouQZhouYChenHWangZTangZLiuJThe efficacy and safety of certolizumab pegol (CZP) in the treatment of active rheumatoid arthritis (RA): a meta-analysis from nine randomized controlled trialsInt J Clin Exp Med20147113870388025550895
   PubMed Web of Science ®Google Scholar
• FerranteMVermeireSRutgeertsPJDrug safety evaluation of certolizumab pegolExpert Opin Drug Saf201413225526624156537
   PubMed Web of Science ®Google Scholar
• Cimzia® (certolizumab pegol) [prescribing information]BrusselsUCB Inc2013 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125160s215lbl.pdfAccessed November 18, 2017
   Google Scholar
• European Medicines AgencyCimzia (certolizumab pegol): summary of product characteristicsLondonEuropean Medicines Agency2014 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdfAccessed November 18, 2017
   Google Scholar
• LoftusEVJrColombelJFSchreiberSSafety of long-term treatment with certolizumab pegol in patients with Crohn’s disease, based on a pooled analysis of data from clinical trialsClin Gastroenterol Hepatol201614121753176227464588
   PubMed Web of Science ®Google Scholar
• YahyaFGaffneyKHamiltonLTumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis-findings from a United Kingdom cohortRheumatology (Oxford)20185761962429272541
   PubMed Web of Science ®Google Scholar
• ElliottABChakravartyEFImmunosuppressive medications during pregnancy and lactation in women with autoimmune diseasesWomens Health (Lond)20106343144020426608
   PubMedGoogle Scholar
• OstensenMBrucatoACarpHPregnancy and reproduction in autoimmune rheumatic diseasesRheumatology (Oxford)201150465766421097449
   PubMed Web of Science ®Google Scholar
• LevyRAde JesusGRde JesusNRKlumbEMCritical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactationAutoimmun Rev2016151095596327490204
   PubMed Web of Science ®Google Scholar
• CalligaroAHoxhaARuffattiAPunziLAre biological drugs safe in pregnancy?Reumatismo201566430431725829190
   PubMedGoogle Scholar
• BazzaniCScrivoRAndreoliLProspectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre studyClin Exp Rheumatol201533568869326311348
   PubMed Web of Science ®Google Scholar
• Götestam SkorpenCHoeltzenbeinMTincaniAThe EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactationAnn Rheum Dis201675579581026888948
   PubMed Web of Science ®Google Scholar
• Weber-SchoendorferCOppermannMWackerEPregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort studyBr J Clin Pharmacol201580472773925808588
   PubMed Web of Science ®Google Scholar
• BrömsGGranathFEkbomALow risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancyClin Gastroenterol Hepatol2016142234234.e1-e5241.e1-e526375613
   PubMed Web of Science ®Google Scholar
• PorterCArmstrong-FisherSKopotshaTCertolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transferJ Reprod Immunol201611671227123565
   PubMed Web of Science ®Google Scholar
• MahadevanUWolfDCDubinskyMPlacental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel diseaseClin Gastroenterol Hepatol2013113286292 quiz e2423200982
   PubMed Web of Science ®Google Scholar
• ClowseMEWolfDCFörgerFPregnancy outcomes in subjects exposed to certolizumab pegolJ Rheumatol201542122270227826523031
   PubMed Web of Science ®Google Scholar
• WardMMDeodharAAklEAAmerican College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritisArthritis Rheumatol201668228229826401991
   PubMed Web of Science ®Google Scholar
• van der HeijdeDRamiroSLandeweR2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritisAnn Rheum Dis201776697899128087505
   PubMed Web of Science ®Google Scholar